Rafferty Asset Management
IBRX icon

Rafferty Asset Management’s ImmunityBio IBRX Stock Holding History

Rafferty Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.03M Sell
346,416
-198,988
-36% -$1.51M 0.01% 543
2026
Q1 		$4.18M Sell
545,404
-61,926
-10% -$424K 0.02% 448
2025
Q4 		$1.2M Buy
607,330
+154,872
+34% +$351K ﹤0.01% 759
2025
Q3 		$1.11M Buy
452,458
+199,990
+79% +$515K ﹤0.01% 776
2025
Q2 		$667K Sell
252,468
-72,081
-22% -$194K ﹤0.01% 829
2025
Q1 		$977K Sell
324,549
-225,356
-41% -$683K ﹤0.01% 746
2024
Q4 		$1.41M Buy
549,905
+94,200
+21% +$392K 0.01% 729
2024
Q3 		$1.7M Buy
455,705
+20,052
+5% +$92.8K 0.01% 675
2024
Q2 		$2.75M Sell
435,653
-874,737
-67% -$5.77M 0.01% 554
2024
Q1 		$7.04M Buy
1,310,390
+570,582
+77% +$2.58M 0.03% 378
2023
Q4 		$3.71M Buy
+739,808
New +$2.32M 0.02% 507
2023
Q1 		– Sell
-471,523
Closed -$2.39M – 1155
2022
Q4 		$2.39M Buy
471,523
+67,083
+17% +$368K 0.02% 527
2022
Q3 		$2.01M Buy
404,440
+120,118
+42% +$547K 0.02% 507
2022
Q2 		$1.06M Sell
284,322
-495,878
-64% -$1.99M 0.01% 625
2022
Q1 		$4.38M Sell
780,200
-45,188
-5% -$277K 0.03% 417
2021
Q4 		$5.02M Buy
825,388
+374,349
+83% +$2.81M 0.03% 388
2021
Q3 		$4.39M Buy
451,039
+33,261
+8% +$366K 0.03% 330
2021
Q2 		$5.97M Sell
417,778
-107,506
-20% -$1.78M 0.04% 276
2021
Q1 		$12.5M Buy
525,284
+465,195
+774% +$12.1M 0.09% 141
2020
Q4 		$801K Buy
+60,089
New +$578K 0.01% 571

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Rafferty Asset Management's IBRX Position: Q2 2026 in Review

Rafferty Asset Management reduced its ImmunityBio (IBRX) stake by 36% in Q2 2026, selling an estimated $1.51M and leaving 346,416 shares worth $3.03M. The position accounts for 0.01% of the portfolio, ranked #543.

Rafferty Asset Management first reported a position in IBRX in Q4 2020 and has held it in 20 quarters since. The position peaked at $12.5M in Q1 2021. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Rafferty Asset Management held 346,416 shares of ImmunityBio worth $3.03M as of Q2 2026.
  • Rafferty Asset Management sold 198,988 ImmunityBio shares in Q2 2026, an estimated $1.51M.
  • ImmunityBio made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #543 holding.
  • Rafferty Asset Management first reported a position in ImmunityBio in Q4 2020 and has held it in 20 quarters since.
  • Rafferty Asset Management's ImmunityBio position peaked at $12.5M in Q1 2021.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.